172 related articles for article (PubMed ID: 36627076)
1. Interaction of psychedelic tryptamine derivatives with a lipid bilayer.
Zohairi F; Khandelia H; Hakami Zanjani AA
Chem Phys Lipids; 2023 Mar; 251():105279. PubMed ID: 36627076
[TBL] [Abstract][Full Text] [Related]
2. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
3. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
Shen HW; Jiang XL; Winter JC; Yu AM
Curr Drug Metab; 2010 Oct; 11(8):659-66. PubMed ID: 20942780
[TBL] [Abstract][Full Text] [Related]
4. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
[TBL] [Abstract][Full Text] [Related]
5. Magic mushroom extracts in lipid membranes.
Nguyen TQT; Lund FW; Zanjani AAH; Khandelia H
Biochim Biophys Acta Biomembr; 2022 Sep; 1864(9):183957. PubMed ID: 35561790
[TBL] [Abstract][Full Text] [Related]
6. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
7. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.
Davis AK; So S; Lancelotta R; Barsuglia JP; Griffiths RR
Am J Drug Alcohol Abuse; 2019; 45(2):161-169. PubMed ID: 30822141
[TBL] [Abstract][Full Text] [Related]
8. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT).
Reckweg JT; Uthaug MV; Szabo A; Davis AK; Lancelotta R; Mason NL; Ramaekers JG
J Neurochem; 2022 Jul; 162(1):128-146. PubMed ID: 35149998
[TBL] [Abstract][Full Text] [Related]
9. A narrative synthesis of research with 5-MeO-DMT.
Ermakova AO; Dunbar F; Rucker J; Johnson MW
J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
[TBL] [Abstract][Full Text] [Related]
10. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking, MM-GBSA, and Molecular Dynamics Approach: 5-MeO-DMT Analogues as Potential Antidepressants.
Kalirajan R; Rishabh K; Srikanth J; Niharika M; Preeya N; Rezaul I
Arch Razi Inst; 2023 Oct; 78(5):1603-1614. PubMed ID: 38590677
[TBL] [Abstract][Full Text] [Related]
12. The potential of 5-methoxy-N,N-dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action.
Tap SC
Addict Biol; 2024 Apr; 29(4):e13386. PubMed ID: 38600715
[TBL] [Abstract][Full Text] [Related]
13. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
Shen HW; Wu C; Jiang XL; Yu AM
Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
[TBL] [Abstract][Full Text] [Related]
14. Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
Barman R; Kumar Bora P; Saikia J; Konwar P; Sarkar A; Kemprai P; Proteem Saikia S; Haldar S; Slater A; Banik D
Phytochemistry; 2024 Feb; 218():113928. PubMed ID: 38035973
[TBL] [Abstract][Full Text] [Related]
15. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
16. 5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines.
Cameron LP; Patel SD; Vargas MV; Barragan EV; Saeger HN; Warren HT; Chow WL; Gray JA; Olson DE
ACS Chem Neurosci; 2023 Feb; 14(3):351-358. PubMed ID: 36630260
[TBL] [Abstract][Full Text] [Related]
17. Trends in DMT and other tryptamine use among young adults in the United States.
Palamar JJ; Le A
Am J Addict; 2018 Oct; 27(7):578-585. PubMed ID: 30260086
[TBL] [Abstract][Full Text] [Related]
18. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM; Eshleman AJ; Forster MJ; Cheng K; Rice KC; Gatch MB
Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
[TBL] [Abstract][Full Text] [Related]
19. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.
Rickli A; Moning OD; Hoener MC; Liechti ME
Eur Neuropsychopharmacol; 2016 Aug; 26(8):1327-37. PubMed ID: 27216487
[TBL] [Abstract][Full Text] [Related]
20. Potentially hallucinogenic 5-hydroxytryptamine receptor ligands bufotenine and dimethyltryptamine in blood and tissues.
Kärkkäinen J; Forsström T; Tornaeus J; Wähälä K; Kiuru P; Honkanen A; Stenman UH; Turpeinen U; Hesso A
Scand J Clin Lab Invest; 2005; 65(3):189-99. PubMed ID: 16095048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
